GlassScriptPhysician profile
David M Frisch
NPI 1033263272
$1,626.20
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $297 · 2021: $27.06 · 2022: $18.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $686.70 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $151.90 | 2019 | |
| Boston Scientific Corporation | $147.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $140.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $131.70 | 2019 | |
| Pfizer INC. | $113.16 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $82.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.72 | 2019 | |
| Abbvie INC. | $27.06 | 2021 | |
| Gilead Sciences, INC. | $21.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2022 | |
| Allergan, INC. | $14.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Frisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.